Joint Corp. (The) (JYNT)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$8.32+0.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · JYNT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 66.3% |
| Our one-year growth estimate | diamond | 5.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 61.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 26 industry peers · Company calendar date is not available
JYNT — earnings miss
Dated 2026-08-06
and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: Changes in credit agreements can impact financial stability. They can also affect growth plans.
Worry ifNo new changes or defaults have been reported in the credit agreement.
Less concerning ifA new change or default has been reported in the credit agreement.
Why it matters: Confirming the sales guidance shows management's confidence in growth. It impacts investor trust.
Watch forSales for 2026 are expected to be between $519 million and $552 million.
Also watch forSales for 2026 are below $519 million.
Why it matters: Better comp sales mean more customers stay and franchises do well. This is key for growth.
Supportive ifQ3 comp sales show improvement, landing above -3% year over year.
Worry ifQ3 comp sales remain below -3% year over year.
Why it matters: If revenue growth picks up, it could signal a stronger market for Joint Corp. and its peers.
Supportive ifHealth Care sector revenue growth is speeding up again. It is close to 10% year over year.
Worry ifRevenue growth is slowing down. It is now below 10% year over year.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$116 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $382 loss on $10,000 · 3.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,791 loss on $10,000 · 27.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: This deal could impact revenue and expansion strategy in the coming months.
Watch forThe Elite Chiro Group deal is done. It has a positive impact on revenue.
Also watch forThere are delays or problems from the Elite Chiro Group deal.
Why it matters: Changes in guidance show management feels good about growth and market conditions.
Worry ifNew guidance says fewer than 22 franchised clinics will open in 2026.
Less concerning ifGuidance for new franchised clinic openings remains at 22 or higher for 2026.
Why it matters: More share repurchases show management believes in the company's value and may help stock price.
Supportive ifManagement announces more share repurchases beyond the $677,000 done in Q2.
Worry ifNo new share repurchases are announced, showing a change in how they use capital.
Why it matters: Changes in credit agreements can affect money management and plans for growth.
Worry ifThere are good updates on credit agreement terms or financial status.
Less concerning ifThere are negative updates or more defaults on credit agreements.
Why it matters: This would show the company is far from its annual revenue goal of $519M to $552M.
Worry ifQ2 revenue was $14.82M or less. This shows a big shortfall.
Less concerning ifQ2 revenue is over $20M. This shows better progress towards the revenue goal.
Why it matters: Meeting or beating adjusted EBITDA guidance shows the company is doing well and is strong.
Supportive ifQ3 adjusted EBITDA hits at least $12.5 million. This matches management's guidance.
Worry ifQ3 adjusted EBITDA drops below $12.5 million. This shows there are operational problems.
Why it matters: Meeting the guidance of $519 million to $552 million shows strong franchise performance. It also reflects management's confidence in growth.
Supportive ifQ3 system-wide sales were over $519 million.
Worry ifQ3 system-wide sales were under $519 million.
Why it matters: The earnings report will show how the company is doing. It will also give future guidance.
Watch forEarnings report shows revenue growth above 5% year over year.
Also watch forEarnings report shows revenue growth below 0% year over year.
Why it matters: Better comp sales would show the business is improving after recent drops.
Supportive ifComp sales improve to above -3% year over year in Q2 2026.
Worry ifComp sales remain below -3% year over year in Q2 2026.
Why it matters: Further M&A activity could enhance growth and market position.
Supportive ifNew M&A deals or partnerships are announced. This is a positive sign.
Worry ifNo new M&A activity is reported. This suggests slower growth.
Why it matters: Meeting or exceeding this revenue target is crucial to achieving annual guidance of $519M to $552M.
Supportive ifQ2 revenue reported at or above $14.82M, indicating strong growth.
Worry ifQ2 revenue falls below $14.82M, showing weak performance.
Why it matters: News about share buybacks shows that management is confident. They focus on how to use capital.
Supportive ifThere is news of more share buybacks beyond the $3.8 million left in the plan.
Worry ifNo news on share buybacks or a pause in the plan. This may signal cash issues.
Why it matters: This growth would indicate a recovery in sales trends after a 4.9% decline in Q1.
Supportive ifQ2 system-wide sales growth exceeds 5% year over year.
Worry ifQ2 system-wide sales growth remains below 0% year over year.
Why it matters: Hitting revenue goals is key for keeping investor trust and helping growth plans.
Supportive ifQ2 2026 revenue meets or exceeds the guidance range of $129M to $138M.
Worry ifQ2 2026 revenue falls below the guidance range.
Why it matters: Finishing refranchising shows a move to a capital-light model. This can boost growth and profits.
Supportive ifAll clinics owned by the company are sold or given to franchisees.
Worry ifDelays in refranchising mean some corporate clinics are still run by the company.
Why it matters: Better cash flow means the company is more efficient and financially healthy.
Supportive ifCash flow from operations rises to over $2.5 million in Q3.
Worry ifCash flow from operations falls below $2 million in Q3.